5 Results for "

LY379268

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "LY379268" in MCE Product Catalog:

  • Targets Recommended:
1
1 Cited Publications
Cat. No.: HY-103558
CAS No.: 191471-52-0
Purity:  99.84%
Target:  

mGluR

Research Areas:  

Neurological Disease

LY379268 is a potent, selective and brain-penetrant mGlu2/3R agonist with EC50 values of 2.69 nM (mGlu2) and 4.48 nM (mGlu3). LY379268 has no activity on human mGlu 1a, 4a, 5a or 7a receptors. LY379268 has antioxidant and neuroprotective effects .
loading...
    loading...
Cat. No.: HY-120717
CAS No.: 2009052-76-8
Target:  

mGluR Cytochrome P450

Research Areas:  

Neurological Disease

VU6001966 is a brain-penetrant and selective mGlu2 receptor inhibitor. VU6001966 blocks mGlu2 receptor activity, counteracts LY379268 (HY-103558)-mediated blood-brain barrier protection and inflammatory cytokine dampening in microglia under inflammatory conditions. VU6001966 enhances antidepressant effects when combined with Scopolamine (HY-N0296). VU6001966 can be used for the research of major depressive disorder .
loading...
    loading...
Cat. No.: HY-103558R
CAS No.: 191471-52-0
Research Areas:  

Neurological Disease

LY379268 (Standard) is the analytical standard of LY379268 (HY-103558). This product is intended for research and analytical applications. LY379268 is a potent, selective and brain-penetrant mGlu2/3R agonist with EC50 values of 2.69 nM (mGlu2) and 4.48 nM (mGlu3). LY379268 has no activity on human mGlu 1a, 4a, 5a or 7a receptors. LY379268 has antioxidant and neuroprotective effects .
loading...
    loading...
Cat. No.: HY-110304
Target:  

mGluR

Research Areas:  

Neurological Disease

NPEC-caged-LY379268 is a type II mGluR agonist .
loading...
    loading...
Cat. No.: HY-118285
CAS No.: 579482-31-8
Target:  

mGluR

Research Areas:  

Neurological Disease

Ro4491533 is a selective, negative allosteric mGluR2/3 receptor modulator that is equally effective on both subtypes. Ro4491533 can completely block glutamate-induced calcium mobilization and glutamate-induced [35S]GTPγS binding accumulation. Ro4491533 has good pharmacokinetic properties in mice and rats, high oral bioavailability, and can pass through the blood-brain barrier. Ro4491533 can also reverse the motor inhibition effect of LY379268 in mice and show antidepressant activity in the forced swim test and tail suspension test.
loading...
    loading...